<DOC>
	<DOC>NCT03018509</DOC>
	<brief_summary>Study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic effect of JTE-451 administered for 4 weeks in subjects with active plaque psoriasis.</brief_summary>
	<brief_title>Study to Evaluate Safety,Tolerability,Pharmacodynamics &amp; Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<criteria>Minimum of two psoriatic plaques (i.e., one clinical target lesion and one biopsy target lesion). Each of the two target lesions must have a psoriatic lesion severity sum (PLSS) of ≥6 Body mass index (BMI) of 18 to 38 kg/m2 (inclusive) Prior exposure to &gt;2 systemic biologic agents and/or small molecules including investigational therapies for the treatment of psoriasis or have not discontinued systemic biologic agents and/or small molecules antipsoriasis therapy including investigational therapies due to lack of efficacy; Subjects with significant health problems, other than having plaque psoriasis (as determined by medical history, physical examination, chest Xray, vital signs and 12lead ECG) that could either interfere with study evaluations or place subject at undue risk; Presence of erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medicationinduced psoriasis at Visit 1; Conditions (e.g., clinicallysignificant eczema or severe acne in the target lesion area) that would interfere with study evaluations; Positive quantiFERON®TB Gold test, negative chest Xray findings for tubercle bacillus (TB) or lack any other evidence of active or latent TB; History of a clinicallysignificant infection (e.g., required oral antimicrobial therapy) within 4 weeks prior to Visit 2; Subjects who do not have clinical laboratory test results within the normal reference ranges (i.e., are deemed not to be clinically significant) or clinically not acceptable to the Investigator;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>JTE-451</keyword>
	<keyword>psoriasis</keyword>
</DOC>